Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$139.3MMiss by $23.1M
EPS-$1.57Miss by $0.03
Revenue estimate$162.4M
EPS estimate-$1.54

Next report

Aug 4, 2026 (In 5 days)
Revenue estimate$183.1M
EPS estimate-$1.21

Financials

Q1 2025

Income statement

See full
Revenue$139.0M+27.7%
Operating income-$143.0M+13.5%
Net income-$151.0M+11.5%
EPS (diluted)-$1.57+22.7%

Balance sheet

See full
Cash & equivalents$127.0M+13.1%
Total debt$38.3M—
Total equity$144.0M+2.7%
Total assets$1.3B+0.4%

Cash flow

See full
Operating cash flow-$166.0M+13.0%
CapEx$1.0M-68.9%
Free cash flow-$167.0M+13.9%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$3.4B-13.6%
Enterprise value$3.31B—
P/S5.8×-3.1×

Profitability

See full
Operating margin-87%-21.9pp
Net margin-93.1%-23.0pp
FCF margin-66.8%-20.5pp

Returns & leverage

See full
Return on equity-386.5%+60.8pp
Debt / equity0.3×—
Current ratio2.4×0.0×

Segments

By geography

See full
North America$58.0M+0.6%
Latin America$55.0M+56.3%
EMEA$23.0M+44.0%
Asia Pacific$3.0M—

By product

See full
Collaboration And Royalty$103.0M+24.7%
Royalty$48.0M+3.6%
Non Cash Royalty$19.0M+5.2%

Versus estimates

Revenue

Q1 2026$136.0MMiss by $22.2MQ4 2025$207.0MBeat by $8.4MQ3 2025$159.9MMiss by $39.8MQ2 2025$166.5MBeat by $547.9K
Q1 2025$139.3MMiss by $23.1M
Q4 2024$164.9MBeat by $6.2M

Diluted EPS

Q1 2026-$1.84Miss by $0.35Q4 2025-$1.29Miss by $0.09Q3 2025-$1.81Miss by $0.58Q2 2025-$1.17Beat by $0.10
Q1 2025-$1.57Miss by $0.03
Q4 2024-$1.39Miss by $0.07

Ask the moment Ultragenyx Pharmaceutical reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Ultragenyx Pharmaceutical report Q1 2025 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Ultragenyx Pharmaceutical's Q1 2025 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $139.3M and eps of $-1.57 for Q1 2025.
Did Ultragenyx Pharmaceutical beat estimates in Q1 2025?
Revenue missed the consensus estimate of $162.4M by $23.1M. EPS missed the consensus estimate of $-1.54 by $0.03.
How did Ultragenyx Pharmaceutical's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 28.0% from $108.8M a year earlier and eps grew 22.7% from $-2.03.
Where can I find Ultragenyx Pharmaceutical's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-064726) directly on SEC EDGAR. The filing index links above go to sec.gov.